ALZpath Broadens Strategic Agreement with Alamar Biosciences to Advance Clinical Diagnostics for Alzheimer's Disease

PartnershippTau217 antibodyPositive

AI Analysis

Summary

ALZpath expanded its strategic agreement with Alamar Biosciences, granting Alamar commercial rights to utilize ALZpath's proprietary pTau217 antibody in blood-based diagnostic tests for Alzheimer's Disease clinical use.

Outcome Details

Expanded strategic agreement granting Alamar commercial rights to utilize ALZpath's proprietary pTau217 antibody in blood-based diagnostic tests for clinical use

Importance:6/10

Sentiment:

0.60

partnershiplicensingdiagnosticsAlzheimer's Diseaseblood testpTau217

Related Companies

$ALMR

Read the original article

Published by PR Newswire Biotech on July 23, 2026 12:30 PM

Read Original